
The Future of DTx
Life Sciences
Case Background
A global pharmaceutical company headquartered in Asia was preparing to launch a next-generation platform-based Digital Therapeutics (DTx) solution, designed to offer patients and healthcare professionals better value compared to legacy options. The primary objective of this solution was to collect data in a self-sustained manner, aiming to create a break-even business model while growing the market and establishing the company's leadership in the associated therapeutic space. Our Client sought to develop an innovative Go-To-Market strategy that would effectively meet both these primary objectives and their secondary goals, ensuring a successful launch and sustained market presence.
We applied the elements of our precedent-based methodology to study relevant Digital Therapeutics (DTx) launches to date and assess conventional and innovative launch strategies side-by-side. This comprehensive analysis included secondary research on both FDA-approved and non-FDA solutions, examining those launched independently as well as through strategic partnerships. The scope of our research was broad, covering various market approaches and success factors. Based on the key findings from our research, the Recombinators team identified the critical elements of a commercial strategy designed to address stakeholder-specific concerns. These concerns ranged from regulatory compliance and market adoption to patient engagement and data security. Our thorough analysis provided a clear understanding of the best practices and potential pitfalls in DTx launches. To further enhance our strategic approach, we conducted a quick precedent search to reveal relevant benchmarks and precedents. These insights fostered novel thinking during an ideation session, enabling us to proposed innovative solutions tailored to our client's unique needs. By leveraging these precedents, we helped our Client pave the way to a robust and effective commercial strategy, ensuring a successful launch and sustainable market presence for the DTx solution.
Our Approach
An in-depth DTx launch analysis highlighted examples of successful GTM strategies, helped to identify key success factors and defined limitations for using conventional approaches in this emerging and rapidly evolving market space. We drafted a detailed patient journey map and identified elements of an integrated scorecard that should be used when measuring the success of the GTM strategy across four distinct groups of stakeholders. Over a dozen of breakthrough GTM solutions were proposed based on the key insights from 27 researched precedents.
Output
The Future of DTx
Life Sciences
Case Background
A global pharmaceutical company headquartered in Asia was preparing to launch a next-generation platform-based Digital Therapeutics (DTx) solution, designed to offer patients and healthcare professionals better value compared to legacy options. The primary objective of this solution was to collect data in a self-sustained manner, aiming to create a break-even business model while growing the market and establishing the company's leadership in the associated therapeutic space. Our Client sought to develop an innovative Go-To-Market strategy that would effectively meet both these primary objectives and their secondary goals, ensuring a successful launch and sustained market presence.
We applied the elements of our precedent-based methodology to study relevant Digital Therapeutics (DTx) launches to date and assess conventional and innovative launch strategies side-by-side. This comprehensive analysis included secondary research on both FDA-approved and non-FDA solutions, examining those launched independently as well as through strategic partnerships. The scope of our research was broad, covering various market approaches and success factors. Based on the key findings from our research, the Recombinators team identified the critical elements of a commercial strategy designed to address stakeholder-specific concerns. These concerns ranged from regulatory compliance and market adoption to patient engagement and data security. Our thorough analysis provided a clear understanding of the best practices and potential pitfalls in DTx launches. To further enhance our strategic approach, we conducted a quick precedent search to reveal relevant benchmarks and precedents. These insights fostered novel thinking during an ideation session, enabling us to proposed innovative solutions tailored to our client's unique needs. By leveraging these precedents, we helped our Client pave the way to a robust and effective commercial strategy, ensuring a successful launch and sustainable market presence for the DTx solution.
Our Approach
An in-depth DTx launch analysis highlighted examples of successful GTM strategies, helped to identify key success factors and defined limitations for using conventional approaches in this emerging and rapidly evolving market space. We drafted a detailed patient journey map and identified elements of an integrated scorecard that should be used when measuring the success of the GTM strategy across four distinct groups of stakeholders. Over a dozen of breakthrough GTM solutions were proposed based on the key insights from 27 researched precedents.